Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip and 3D-Culture: Companies, Technologies and Approaches

Tania Konry's Biography

Tania Konry, Assistant Professor, Department of Pharmaceutical Sciences, Northeastern University

Dr.Konry’s laboratory at Northeastern University is focused on developing novel Bio-MEMS approaches to advance point of care diagnostics, cell culture and drug screening and delivery methods. She has developed Lab-on-a-Chip (LOC) devices that integrate several laboratory functions such as real time monitoring of target clinically relevant analyte, proteomics, genomics, cell-cell interactions as well as cell secretion and surface monitoring of single cells on a micro-chip. Her single cell project was awarded with NIH and NSF grants. Dr.Konry was nominated as Phase 1 Finalist of Follow That Cell Challenge/NIH and spotlighted in GEN magazine on her work in single-cell work. She also was recognized with Schumacher Faculty Award, presented to one faculty member early in their Northeastern career for significant academic achievement at Northeastern University and received a competitive BD Biosciences immunology research award for analyzing immune-tumor cell interactions in dynamics with single cell resolution.

Tania  Konry Image

Biomimetic Tissue-Engineered Technology to Identify Tumor-Stroma Cross Talk and Novel Drug Candidates

Tuesday, 11 July 2017 at 15:00

Add to Calendar ▼2017-07-11 15:00:002017-07-11 16:00:00Europe/LondonBiomimetic Tissue-Engineered Technology to Identify Tumor-Stroma Cross Talk and Novel Drug

Development of a physiologically relevant and reproducible in vitro cancer model for preclinical and pharmacological studies continues remains a critical unmet need. Two-dimensional (2D) tissue culture models and monolayer cultures lack realistic complexity of TME and tumor heterogeneity, while the current methods of ex vivo 3D tumor models suffer from number of drawbacks including a) inconsistencies related to achieving uniformity of spheroid size, cell–cell and cell–matrix interactions, b) not suited for high-throughput screening assays and c) the difficulty to limit shear-related cell damage. A variety of microfluidic device designs have been utilized for long-term tumor spheroid culture and drug efficacy evaluation, however, most lack the integral TME and dynamic perfusion and/or influence immune-tumor cross-talk or/and prolong culture capabilities.  Our innovative microfluidic platform technology is focused to generate biomimetic multicellular immunogenic spheroids. The proposed technology is based on integrated high-throughput microfluidic droplet based device capable of sequential generation, maintenance via continuous perfusion, stimulation and monitoring cellular dynamics of Alginate (Alg)-doped based micronized tumor spheroids. The Alg - doped hydrogel provides the mechanical strength to maintain the structural integrity of the spheroids and permit cellular encapsulation to mimic several important aspects of the in vivo environment such as a synthetic extracellular matrix (ECM), which promotes attachment of stroma cellular integrins to initiate signaling for cell survival and simulate the TME. We examined its capability to (1) allow recreation of TME and pathophysiological gradients to mimic the resistance to drug penetration; (2) cell composition and heterogeneity of the  tumor to evaluate tumor cell survival in real-time; (3) investigate spatiotemporal interaction between cancer-stroma and cancer-immune cells during therapy; and (4) capture the dynamic data such as secretome analyses from lymphocyte and stroma cells that exert paradoxical effects in the TME, changes in cellular proliferation, and viability and migration in the presence and absence of immune and stromal cells. We hypothesize that a precisely defined spheroid size and composition at the onset of treatment will clearly affect and predict response to treatment. Our platform provides a novel yet overall simple in vitro platform that will generate and analyze 3D monodisperse hydrogel tumors for biologic studies and therapeutic drug screening, which is a critical step in the translational cancer drug development.

Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonOrgan-on-a-Chip and 3D-Culture: Companies, Technologies and